Li Auto downgraded at HSBC saying co’s recovery still out of sight

Investing.com — December 2025 opens with a fresh wave of macro uncertainty as markets digest the latest labor market report, which signaled cooling job growth and stirred debate over the Federal Reserve’s next steps on interest rates. Tech stocks, already under pressure after sliding over the past 30 days, continue to feel the weight of shifting expectations around monetary policy and corporate earnings. With sentiment fluctuating and volatility elevated, investors are navigating a landscape where narratives can change quickly.

In moments like this, relying solely on emotion or headlines can cloud judgment. Data-driven, AI-powered insights have become increasingly valuable for identifying emerging trends before they gain broader attention. Our proprietary Tech Titans strategy leverages machine learning models to distill the data from the noise and spotlight high-conviction tech names showing early-month strength. Even just a few days into December, several of these signals are already posting notable gains, offering an early read on this month’s momentum.

Here’s how some of our big winners are performing so far:

• Amkor Technology (NASDAQGS:AMKR): +16.64% in December ALONE
• ON Semiconductor (NASDAQGS:ON): +13.33% in December ALONE
• Entegris (NASDAQGS:ENTG): +13.08% in December ALONE

Among several others...

Want to see the full list of tech stocks that our AI flagged as high-conviction choices for December?

*InvestingPro members can click HERE to jump straight to our full list of December tech picks.

Still not a member? Now is your chance to join at up to 55% off and get instant access to our complete list of AI-picked tech stocks FOR LESS THAN $8 A MONTH.

Proven performance that keeps compounding

250K+ investors trust InvestingPro’s AI strategies, and the results continue to reinforce why. The same engine powering December’s early winners has consistently delivered exceptional results over the last two years.

Our Tech Titans strategy is now up +153.34% since its launch in November 2023.

The strategy doesn’t chase trends; it identifies durable opportunities in semiconductors, automation, cloud infrastructure, and other high-growth categories and then continually refines its selections.

Here’s why our AI selected Amkor Technology during its last rebalancing on December 1:

• Strong recent momentum with a 103% six-month gain and trading near its 52-week high.
• Q3 outperformance with EPS and revenue beating forecasts, showing solid operational strength.
• Key partnerships with Nvidia and Apple enhance exposure to AI and high-performance computing demand.
• Major $7B Arizona packaging facility signals long-term growth supported by CHIPS Act incentives.
• Valuation remains reasonable, and analysts expect 65% EPS growth through 2027.

But how does the AI behind these picks actually work?

At the start of each month, the AI refreshes every strategy with up to 20 new stock picks, analyzing more than 150 investor-grade financial models built on over 15 years of global market data. It identifies where risk and reward align best — removing underperformers, keeping promising names, and adding fresh opportunities.

Each decision is backed by a rationale that clarifies why a stock was added, removed, or kept in the strategy.

The strategies use equal weighting across all selected stocks, creating a transparent and consistent way to track results. The goal is not just to find winners but also to know when to move on from the ones that stop performing.

Check out the 12-year outperformance of Tech Titans over the S&P 500 below:

This means a $100K principal in our strategy would have turned into an eye-popping $2,757,500.

Use your chance to get InvestingPro now for less than $8 a month during our Cyber Monday Extended sale.

Disclaimer: Prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.

Investing.com -- RBC Capital Markets sees humanoid robots emerging as one of the most transformative technologies of the coming decades, outlining a combined hardware and software opportunity that could reach roughly $12 trillion by 2050.

The brokerage estimates a $9 trillion total addressable market (TAM) for humanoid hardware, with an additional $3 trillion potential from software and services layered on top

{{pro_promotion | Unlock deeper research on robotics, AI, and top Wall Street stock calls by upgrading to InvestingPro - get 55% off today}}

Household use is viewed as the largest long-term segment, though full-featured domestic robots may take more than 20 years to mature.

Narayan highlights China as the dominant geography, accounting for about 61% of the projected hardware TAM due to faster adoption, manufacturing scale, and supportive policymaking.

Unit costs could fall to around $25,000 as production scales, enabling broad deployment across households, factories, and retail environments.

Household demand alone is estimated to reach roughly $2.9 trillion, reflecting both high penetration potential and the likelihood that families may eventually own multiple units.

Narayan believes the economics of humanoids could mirror a hybrid of cars and smartphones. Robots would be sold as one-time capital goods, but ongoing software revenue—via app-store ecosystems and skill downloads—could become a major profit driver.

In an upside case, “software subscriptions and app sales could add ~$3T to the estimated ~$9T TAM,” creating a recurring, high-margin layer similar to Apple’s services model.

Competition remains wide open. The analyst stresses that “the humanoid robotics market is highly fragmented, with no clear leaders yet emerging.”

Tesla, Boston Dynamics, Unitree, UBTECH, Figure AI and Apptronik are identified as prominent players, though each is still developing core capabilities.

Chinese firms lead on hardware scale and cost efficiency, while the U.S. and Europe have an edge in software, autonomy and advanced AI.

RBC also outlines broad investment implications across the value chain, from sensors, actuators and cameras to operating systems, interoperability frameworks and design-focused consumer robotics.

While industrial and commercial applications are expected to scale first, Narayan sees long-term potential for humanoids to surpass the global auto fleet, given their ability to operate frequently and across a far wider set of tasks.

Investing.com -- Bill Holdings Inc. (NYSE:BILL) stock rose 2.2% Thursday after Bloomberg reported that activist investor Barington Capital Group has taken a stake in the business payments firm and is urging its board to explore a sale.

Barington has built a roughly $25 million position in Bill Holdings and joins other activist investors Elliott Investment Management and Starboard Value LP who already have stakes in the company. The hedge fund is now engaging with the company, according to people familiar with the matter.

"Based on our research, it is our belief that the company would be an extremely attractive acquisition candidate for both strategic and financial buyers," Barington Chief Executive Officer James Mitarotonda wrote in a letter to Bill’s board that was reviewed by Bloomberg News.

In the letter, Mitarotonda called on the board to "engage a financial adviser and form a special committee of independent directors to explore strategic alternatives for the company, including a potential sale, merger or other business combination."

The news comes as Bill Holdings faces increasing pressure from activist investors to consider strategic options that could potentially unlock shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock rose 3.6% Thursday after the company announced its official expansion into the Canadian market, marking a significant step in its international growth strategy.

The health and wellness platform’s entry into Canada follows its recent acquisition of Livewell, a Canadian digital health platform specializing in weight loss treatments. This strategic move positions the company to launch its comprehensive weight loss program in Canada next year, coinciding with the anticipated availability of generic semaglutide.

The expansion addresses a critical need in Canada, where nearly two-thirds of adults are overweight or living with obesity, yet face limited access to effective treatments due to high costs and other barriers. To support this new market, Hims & Hers has appointed Austin Kouri as General Manager of Canada and Dr. Sandy Van as Chief Medical Officer in Canada.

"Our expansion into Canada is a direct response to critical public health needs, particularly around the obesity crisis," said Andrew Dudum, co-founder and CEO of Hims & Hers. The company completed the all-cash acquisition using funds from its existing balance sheet.

The company, which already operates in the United States and Europe, views this expansion as part of its broader mission to democratize access to personalized healthcare globally. Hims & Hers plans to continue expanding into additional specialties in Canada and other international markets as demand for personalized healthcare access grows.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- uniQure N.V. (NASDAQ:QURE) stock fell 14% after the gene therapy company received feedback from the U.S. Food and Drug Administration (FDA) indicating that current data for its Huntington’s disease treatment is unlikely to support approval.

The FDA conveyed in final meeting minutes from an October 29 pre-Biologics License Application meeting that data from Phase I/II studies of AMT-130 would probably not provide sufficient primary evidence to support a BLA submission. This feedback confirms what uniQure had previously disclosed in a November 3 press release.

uniQure is currently evaluating the FDA’s feedback and plans to request a follow-up meeting with the regulator in the first quarter of 2026 to discuss next steps for the investigational gene therapy.

"We are committed to collaborating with the FDA to advance AMT-130 to patients and their families as rapidly as possible," said Matt Kapusta, chief executive officer at uniQure. "The support we have seen these last weeks from the Huntington’s disease community, including patients, families, caregivers, clinicians and advocates reinforces the urgency of the unmet need in Huntington’s disease."

AMT-130 is being developed as a potential treatment for Huntington’s disease, a rare genetic disorder that causes the progressive breakdown of nerve cells in the brain, leading to movement, cognitive, and psychiatric disorders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.